Procept BioRobotics reported strong Q2 2025 financial results with 48.3% revenue growth, reaching $79.2 million, driven by increased U.S. and international sales of robotic surgical systems for BPH treatment.

PROCEPT BioRobotics announced leadership transition with Dr. Reza Zadno retiring and Larry L. Wood becoming the new president and CEO effective September 2, 2025. The company also pre-announced Q2 2025 revenue of $79.2 million, representing 48% annual growth.

PROCEPT BioRobotics announced a new Category I CPT code for Aquablation therapy, effective January 1, 2026, with Medicare payment rates comparable to traditional TURP procedures, signaling broader recognition and potential adoption of their BPH treatment technology.

Several mid-cap stocks, including Globalstar, V.F. Corp, and Madrigal Pharmaceuticals, were among the top gainers last week. The companies reported positive financial results and business updates, leading to the stock price increases.

PROCEPT BioRobotics announced FDA clearance of its next-generation HYDROS Robotic System, which features AI-powered treatment planning, advanced image guidance, and robotic resection to deliver improved efficiency, enhanced user experience, and better clinical outcomes for Aquablation therapy.

SAN JOSE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that the American Medical Association (“AMA”) has established a new Current Procedural Terminology (“CPT”) Category I code for transurethral waterjet resection of prostate tissue (“Aquablation therapy”) to treat benign prostatic hyperplasia (“BPH”).

SAN JOSE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Truist Securities MedTech Conference in Boston, Massachusetts. Management is scheduled to present on Tuesday, June 18 at 1:20 p.m. Eastern Time.

SAN JOSE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas. Management is scheduled to present on Wednesday, May 29 at 10:20 a.m. Eastern Time. Additionally, members of management will present at the upcoming 44th Annual William Blair Growth Stock Conference in Chicago. Management is scheduled to present on Tuesday, June 4 at 5:00 p.m. Eastern Time.

4 analysts have shared their evaluations of PROCEPT BioRobotics (NASDAQ:PRCT) during the recent three months, expressing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 0 0 0 Last 30D 1 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 0 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $70.0, with a high estimate of $75.00 and a low estimate of $58.00. Witnessing a positive shift, the current average has risen by 12.0% from the previous average price target of $62.50. Deciphering Analyst Ratings: An In-Depth Analysis In examining recent analyst actions, we gain insights into how financial experts perceive PROCEPT BioRobotics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Joshua Jennings TD Cowen Raises Buy $75.00 $65.00 Matt O'Brien Piper Sandler Raises Overweight $75.00 $67.00 Richard Newitter Truist Securities Raises Buy $72.00 $63.00 Richard Newitter Truist Securities Raises Buy $58.00 $55.00 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to ...Full story available on Benzinga.com

Data from the Icahn School of Medicine at Mount Sinai and Potomac Urology presented at the 2024 AUA Annual Meeting highlight Aquablation therapy’s potential to become the new standard of care in BPH for prostates of all sizes Data from the Icahn School of Medicine at Mount Sinai and Potomac Urology presented at the 2024 AUA Annual Meeting highlight Aquablation therapy’s potential to become the new standard of care in BPH for prostates of all sizes

PROCEPT BioRobotics (PRCT) delivered earnings and revenue surprises of 7.27% and 6.88%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

SAN JOSE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter of 2024 after market close on Wednesday, May 1, 2024. The Company’s management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time.